Category: Biotech

July 25, 2024

The use of artificial intelligence (AI) is seeing a surge in a variety of industries. But does the regulated nature of bio/pharmaceutical development, manufacturing, and commercialization serve up unique challenges for incorporating AI into processes? According to Siegfried Schmitt, vice-president, […]

July 22, 2024

At the start of 2024, optimism had returned to biotech. Investor cash flowed back toward drug companies and initial public offerings, a useful barometer of the sector’s health, picked up in a sign of the market’s strengthening. But IPOs have […]

July 10, 2024

Flagship’s robust funding round highlights a general recovery in biotech investment. A number of venture capital firms brought in fresh cash this year, including Foresite Capital, Sands Capital, Scion Life Sciences and a life sciences arm of Goldman Sachs. Arch […]

May 15, 2024

TSLP has become a popular target for drugmakers looking for new ways to tackle inflammation. Amgen and AstraZeneca entered the market first, after winning Food and Drug Administration approval in late 2021 for the asthma treatment Tezspire, an injection designed […]

May 14, 2024

Sands Capital has closed its latest life sciences investment fund, a $555 million haul that could help support biotechnology companies preparing to go public. The fund announced Tuesday, named Sands Capital Life Sciences Pulse Fund III, is the firm’s third […]

May 2, 2024

Cancer research is always evolving, as scientists search for ways to combat the tricks tumors use to evade drug therapies. In the last decade alone, immunotherapies, targeted therapies, antibody-drug conjugates and radiopharmaceuticals have become standard treatment for a variety of […]

April 12, 2024

Initial public offerings by biotechnology companies reached pre-pandemic levels during the first quarter, with nine drugmakers collectively raising more than $1.3 billion, according to BioPharma Dive data. The sum is more than three times the $375 million in total proceeds […]

April 11, 2024

Drugmakers are moving quickly to study whether cell therapy, already a proven treatment for certain blood cancers, can tamp down autoimmune conditions, too. Lupus, a chronic disease that can cause inflammation and pain across the body, is one of the […]

February 14, 2024

A little over four years ago, biotechnology giant Amgen retreated from neuroscience research, halting much of its work developing treatments for diseases of the brain and trimming associated staff. Amgen’s pivot proved a boon for a small startup that was […]

February 12, 2024

Six biotechnology startups are merging into a new skin drug developer called Alys Pharmaceuticals, which launched on Monday with $100 million from European life sciences investment firm Medicxi. Alys was formed out of the merger of a group of biotechs […]

February 2, 2024

Arch Venture Partners, one of the biotechnology sector’s most prolific company creators, is raising a new $3 billion fund, according to a regulatory filing. The fund, which would be Arch’s 13th, is being put together less than two years after […]

January 26, 2024

Wilmington, Delaware-based Synnovation, a specialist in small-molecule therapeutics for cancer, has emerged from the shadows with a $102 million first-round financing led by Third Rock Ventures with participation from Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management. The […]

January 24, 2024

Cancer drug developer CG Oncology has raised $380 million in an initial public offering than was larger than it expected, a positive sign for a sector that’s struggled to generate demand from Wall Street investors recently. The company on Wednesday […]

January 19, 2024

Blue Owl Capital and Canada Pension Plan Investment Board have stepped in to bulk up cash reserves at BridgeBio as it prepares for the launch of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) and a market showdown with much larger rival […]

January 18, 2024

Mirae Asset Capital Life Science, a new venture capital fund, launched on Thursday, joining several other new firms that have recently emerged with plans to invest in drug startups. The fund is a spinout of Mirae Asset Financial Group, a […]

January 17, 2024

More than two years after the bottom fell out for biotech stocks, the market for IPOs is showing early signs of life, though investors are generally looking for more well-established companies than in the past. Four of the five companies […]

January 16, 2024

CellVoyant—an artificial intelligence (AI) first biotechnology company spun out of the University of Bristol—has raised £7.6 million in seed funding to speed up the development of novel cell therapies. According to a Jan. 16, 2024 press release, the funding was […]

January 11, 2024

The J.P. Morgan Healthcare Conference, a yearly temperature taker for the biotechnology industry, had a different feel in 2024. For the first time in awhile, young drugmakers and their backers were optimistic the sector’s downturn might finally be over. An […]

January 9, 2024

The deal – announced at the JP Morgan Healthcare conference this week – includes a sizeable $1 billion upfront payment, with up to $400 million more on the table if Aiolos’ pipeline delivers the results GSK is hoping for. AIO-001 […]

November 30, 2023

Flagship Pioneering is looking to raise $3 billion for its eighth venture fund, a sign the high-profile company creator continues to see investor interest in the biotechnology sector despite a turbulent market. The plans were outlined in a securities document […]